Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effectiveness of ColoVisano with view to the nonspecific pain syndrom of the locomotor system, particularly of the back, was proven on 3,326 ambulant patients. Three weeks after starting of treatment the majority of the patients was found free of pain. Considering the duration of the disease, the result of treatment with DoloVisano is remarkable: 66% = very good--good, 17% = moderate, only 12% = without success. Only in 15% of the cases side effects were found, which never led to an interrupture of the treatment. When listing the side effects, gastric pain with 6% and trousiness with 50% are ranging among the first places. The field study, performed by 314 orthopedic doctors in practice shows the high effectiveness of DoloVisano not only in patients with non-specific pain syndrom resulting from the spine but also with rheumatic syndrom, especially fibrositis and degenerative diseases.
 ...
PMID:[Results of treatment with DoloVisano for non-specific pain syndrome related to body movement. Concluding report on a field study of 3326 patients by 314 orthopedists]. 45 89

A combined behavioral-psychodynamic treatment for severe, chronic stomach pain has been presented. In the case discussed, neither psychotherapy nor behavior therapy alone was successful in dealing with the patient's somatized depression. Aversive conditioning was credited with eliminating verbal report of pain and subjective sensation of chronic gastric pain. Simultaneous with the reduction in pain, however, the patient became increasingly depressed. Analytically oriented psychotherapy was instrumental in resolving the depression.
Pain 1977 Oct
PMID:Aversive behavior therapy for chronic stomach pain: a case study. 92 82

The pattern of gastrointestinal symptoms and select mood and somatic symptoms was examined across two menstrual cycles in women with (n = 19) and without (n = 39) functional bowel distress (FBD). The women (a) rated their gastrointestinal, perimenstrual, mood, and other symptoms and stool frequency and consistency daily; (b) completed the Menstrual Distress Questionnaire-T; and (c) had serum levels of estrogen and progesterone measured during the menses, follicular, and luteal phases. Stomach pain, nausea, and diarrhea were rated higher at menses in the group with FBD than in the group without FBD. Stomach pain was higher during the remaining days as well. The group with FBD reported higher levels of perimenstrual symptoms also on six of the eight Menstrual Distress Questionnaire-T subscales (P less than 0.01). Other complaints, e.g., poor work/school performance, were higher in women with FBD, but somatic symptoms that were expected to vary over the cycle did not differ between groups, except cramping pain. There were no significant group differences in ovarian hormone levels or stool consistency/frequency scores.
 ...
PMID:Pattern of gastrointestinal and somatic symptoms across the menstrual cycle. 173 22

Dihydroergokryptine has been evaluated in the prophylaxis of headache attacks in patients with migraine without aura. The study was controlled vs dihydroergotamine with a double-blind crossover design. After a 1-month run-in period, 30 patients were randomized into two groups and submitted to 4 months treatment with dihydroergokryptine 10 mg b.i.d. or dihydroergotamine (controlled release) 5 mg b.i.d. The treatment was repeated in crossover after 2 months washout. The clinical patients' evaluation was determined by monthly Pain Total Index recording, headache days/month and analgesic consumption. The patients were considered responsible when Pain Total Index decreased by 50% or more in 1 or more months of each treatment period; otherwise the patients were considered unresponsive. The response rate to dihydroergokryptine was 66% while 48% of cases were responsive to dihydroergotamine. The response rate to both treatments was 41%, while 26% did not respond to either treatment. Seven cases unresponsive to dihydroergotamine responded positively to dihydroergokryptine while two cases only, resistant to dihydroergokryptine, responded positively to dihydroergotamine. Three cases dropped out during treatment with dihydroergotamine due to gastric pain and nausea, while they did not show any side effects during dihydroergokryptine therapy. During treatment with dihydroergokryptine there was one case of skin rash which disappeared after drug withdrawal. In conclusion, dihydroergokryptine appears to be an effective drug for the prophylaxis of migraine attacks.
 ...
PMID:Dihydroergokryptine versus dihydroergotamine in migraine prophylaxis: a double-blind clinical trial. 190 3

Two groups, each composed of 20 elderly patients suffering from osteoarthritis characterised by intense pain, were treated for 4 weeks with the oral formulation of two modern oxicam derivatives (tenoxicam capsules and beta-cyclodextrin-piroxicam tablets respectively). The analysis of the results showed that both drugs have an excellent antalgic effect. After the first dose the action of beta-cyclodextrin-piroxican was quicker and more marked, with statistically significant differences between treatments for the first 4 hours. At the end of the study period the two drugs proved to be equally effective, with a more pronounced symptomatic effect of beta-cyclodextrin-piroxican. No side effects serious enough to warrant suspension of treatment were observed: the only side effects reported were gastric adverse events (pyrosis, gastralgia) in both groups, having an incidence of 50% (tenoxicam) and 15% (beta-cyclodextrin-piroxicam) respectively.
 ...
PMID:[Osteoarthritic disease: therapy with oxicam derivatives]. 210 68

Twenty patients, 10 males and 10 females, age range 32-76, mean age 57.80 years, with diagnoses of acute multiple joint disorders (9 cases), flare-ups of rheumatoid arthritis (4 cases), low back pain due to lumbosacral disc pathology (4 cases), osteoarthritis of large joints (3 cases), all with severe pain and corresponding functional limitation of the joints involved, were treated with a nabumetone preparation (1 g capsules; one capsule at night before going to bed) for 8-12 days. During treatment, symptoms subsided gradually with adequate recovery of joint function. Parameters concerning general tolerability did not reveal clinically relevant changes compared to baseline. Local tolerability was mostly satisfactory. Two patients complained of mild side effects (gastric pain and skin phenomena). Treatment was considered effective in 15 cases, scarsely effective in 4, and ineffective in one.
 ...
PMID:[Treatment of acute rheumatic-articular diseases with nabumetone]. 214 18

Twenty patients, 7 males, 13 females, age range 27-69, average 46 years, with highly painful and inflammatory osteo-articular pathology were treated with a nabumetone preparation (one 1 g capsule at night before going to bed), for a minimum of 6 and a maximum of 10 days (average 9.70 days). Already during the first days of treatment, pain and joint function were improved and reactive edema diminished. The authors believe the drug to have a preventive analgesic effect which may at first consist in an increased pain threshold at the level of capsular receptors and may subsequently involve algoreceptors situated in the tendons. In addition to its analgesic efficacy, the drug has the advantage of being easy to handle neither general nor local side effects were observed. Only two patients complained of digestive side effects (dyspepsia and minor gastric pain in one case; gastric pain and vomiting in the other: both leading to withdrawal of the drug after 6 days). Five patients had excellent results, 9 reported good results, in 5 the result was fair.
 ...
PMID:[Analgesic and anti-inflammatory effect of nabumetone in osteo-articular diseases in the acute phase]. 214 82

The etiology of gastric pain is an unsolved riddle, despite nearly a century of research. While much research and many pharmacologic treatment methods have been aimed at controlling acid secretion, the role of acid in reports of pain is unclear. In this study, 30 patients (10 with endoscopically verified duodenal ulcers, 10 with verified nonulcer dyspepsia, and 10 healthy volunteers) participated in a double-blind crossover study of the effects of ranitidine on pain reports after an injection of pentagastrin. The results showed that whereas pentagastrin caused a significant increase in gastric secretion, only the patients with nonulcer dyspepsia reported any appreciable pain before or after the injection. In addition, they chose more adjectives to describe their pain and reported more symptoms, especially directly after the injection. There were no significant differences between the drug and placebo conditions nor between the ulcer and healthy subjects. The role of acid in reported pain remains unclear.
 ...
PMID:Blocked and nonblocked acid secretion and reported pain in ulcer, nonulcer dyspepsia, and normal subjects. 236 9

Gastrointestinal (GI) functional indicators and symptoms across the menstrual cycle were examined in three groups of women: dysmenorrheic (n = 15), non-pill-taking nondysmenorrheic (n = 10), and nondysmenorrheic taking birth control pills (BCPs) (n = 9). Group assignment was based on the reported presence or absence of moderate to severe menstrual cramps in a GI Health Diary which subjects kept for two menstrual cycles. Stool consistencies and frequencies and GI symptoms were also recorded in this diary. Menstrual cycle phase significantly, p = .03, influenced stool consistencies for the sample as a whole with the loosest stools at menses. Reports of stomach pain were higher, p less than .001, at menses than at other cycle phases in all groups, and nausea, p less than .001, and decreased food intake, p less than .01, were more frequently reported by dysmenorrheic women at menses. More dysmenorrheic women had a history of menses-related GI symptoms. Both cycle phase and group differences were significant, p less than .05, for menstrual distress, with negative affect, pain, behavior changes, and autonomic reactions reported more frequently at menses by dysmenorrheic women.
 ...
PMID:Gastrointestinal symptoms and bowel patterns across the menstrual cycle in dysmenorrhea. 334 18

In this trial, 20 patients suffering from bone metastasis pain received diclofenac, a non-steroid anti-inflammatory agent, by continuous IV infusion. No pain was observed in 77% after 2.7 days of treatment. 33% of bedridden patients were able to move again. Two patients (10%) presented gastric pain controlled by symptomatic treatment.
 ...
PMID:[Efficacy of diclofenac continuous perfusion in hyperalgic bone metastases. Apropos of 20 cases treated at Gustave Roussy Institute]. 341 88


1 2 3 4 5 6 7 8 Next >>